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Background:  Pressure overload (POL) promotes LV remodeling which may progress to heart failure (HF). HF is characterized by neurohumoral 
activation which promotes sodium retention and activates pathways which may modulate mTOR signaling. We hypothesized that effects of mTOR 
inhibition (rapamycin, RAPA) on autophagy and LV remodeling may be altered in POL associated with HF.
Methods:  Reduced ejection fraction (EF) at 3 wks post transverse aortic constriction (TAC) correlates with severe remodeling and HF (increased 
lung weight). Thus, male C57BL/6 mice underwent TAC and 3 wks later TAC mice were designated compensated (COMP, EF≥65%) or HF (EF<65%) by 
echo. Each group was treated with RAPA or vehicle for 6 wks. Autophagy (increased microtubule-associated protein light chain 3-II (LC3-II), marker of 
autophagosome formation) was assessed.
Results:  In untreated mice, COMP had normal lung weight and less severe remodeling than HF. Compared to non-TAC, untreated COMP and HF had 
no change in LC3-II. RAPA (trough level = 11±7 ng/ml) ameliorated LV remodeling in both groups. LC3-II was higher in RAPA treated HF mice. 
Variable (mean±SD) Non-TAC COMP
COMP+
RAPA
HF HF+RAPA p-ANOVA
n 9 7 9 13 13
EF at end study, % 83±4 69±8 *† 74±6* 31±9* 61±1*‡ <0.001
LV:body weight, mg/g 3.12±0.35 5.06±1.52*† 3.93±0.81‡ 7.49±1.19* 5.02±0.83*‡ <0.001
Lung:body weight, mg/g 5.87±0.78 6.93±1.45† 6.41±1.20 14.47±5.10* 9.04±3.39*‡ <0.001
End Systolic LV Pressure, mmHg 103±17 146±25* 138±26* 123±13 151±28*‡ 0.004
LC3-II, arbitrary units relative to 
non-TAC
1.00±0.11 1.05±0.20 0.99±0.36 1.02±0.14 1.46±0.36*‡ 0.003
*p<0.05 vs non-TAC; † p< 0.05 untreated COMP vs HF; ‡ p<0.05 RAPA treated vs respective untreated group (HF or COMP)
Conclusion: mTOR inhibition reversed LV remodeling in severe established HF and COMP hypertrophy. Increased autophagy was associated with 
the ameliorative effects of mTOR inhibition in HF. Autophagy stimulators may provide benefit in HF.
